Psychedelic Stocks Archives - Page 46 of 61

TuesdayAug 09, 2022 1:59 pm

Compass Pathways to Begin New Phase 2 Psychedelic Trial for Anorexia

Compass Pathways PLC (NASDAQ: CMPS) is a mental health care company that is focused on improving patient access to evidence-based innovation in mental health. The company’s stock, which trades as CMPS on the NASDAQ has been performing well, with many attributing this positive performance to the appointment of a new CEO. The company recently announced that it would be launching a new phase 2 trial on the use of its COMP360 formulation in treating anorexia. The company will conduct the trial at various prestigious research institutions in the United States and the United Kingdom, including Columbia University’s Irving Medical Center,…

MondayAug 08, 2022 2:31 pm

Toronto Firm Receives First Federal Government Funding to Study Psilocybin

After decades of prohibition, Canada is finally opening the door to psychedelic research. Canada banned psychedelics nearly 50 years ago, outlawing the production and use of psychedelic drugs such as psilocybin, the main psychoactive agent in magic mushrooms, and making it nearly impossible to research these drugs. However, the winds have been shifting in favor of psychedelics in recent years as more people have begun using them to address mental health conditions including (PTSD) and major depressive disorder. A Toronto-based company has now received Canada’s first-ever federal government funding to run a study on the impact of psilocybin on depression.…

ThursdayAug 04, 2022 12:55 pm

Three Clinical Trials On Psychedelic Microdosing Worth Following

As more research on the therapeutic benefits of psychedelics is conducted, concerns about whether microdosing works continue to grow, as many believe that the supposed benefits may be solely because of the placebo effect. It doesn’t help that data from placebo-controlled trials is inconclusive, which only means that the best way to find out whether microdosing is actually effective is to carry out properly controlled microdosing clinical trials. The following are a few of the ongoing microdosing clinical trials. Filament Health’s psilocybin clinical trial Earlier in the year, Filament Health announced that it was launching a phase II psilocybin microdosing…

WednesdayAug 03, 2022 12:33 pm

New Poll Finds Most Americans Support Research on Psychedelics for Military Members

A recently conducted poll has found that most Americans support the study of substances such as MDMA and psilocybin as alternative options for mental health treatment for military service members. Bipartisan legislators championing for policy issues such as the promotion of research on psychedelics and the legalization of cannabis appear to have plenty of support from Americans, despite Congress receiving criticism for not aligning with its constituents on such matters. The YouGov poll, which was conducted between July 22—25, 2022, found that nearly 55% of Americans were in favor of permitting studies into the therapeutic potential of a range of…

TuesdayAug 02, 2022 1:22 pm

Fruitfly Research Model Finds That Single Psilocybin Dose Has Long-Lasting Antidepressant-Like Effects

A new study has looked into the effects of psilocybin at a genetic and cellular level using fruit flies, because their neurotransmitter systems are similar to those of mammals. This has led to the discovery that one dose of the active compound produces a long-lasting, antidepressant-like effect in fruit flies. Psilocybin is the active compound found in magic mushrooms that produces changes in time perception, sensory perception, mood and sense of self. This can alter the way an individual experiences the world around them. Preliminary studies have shown that administering psilocybin in conjunction with psychotherapy may result in lasting improvements…

MondayAug 01, 2022 11:37 am

The DEA Rescinds Proposal to Ban Five Psychedelics

The Drug Enforcement Administration (DEA) recently withdrew a proposal to ban certain psychedelics, stating that it had instead decided to request for an updated review of the psychedelic compounds from the Department of Health and Human Services (DHHS). The DEA had first proposed that the DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPTtryptamines be scheduled earlier in the year. Tryptamines are psychedelic and hallucinogenic drugs that cause users to experience hallucinations as well as euphoria. However, after the announcement, the agency faced criticism on the matter and received hundreds of messages opposing the change and asking for a hearing. Through its own…

FridayJul 29, 2022 12:03 pm

Research Finds Psychedelics May Open Door to Self-Actualization

According to Maslow’s Hierarchy of Needs, self-actualization is the realization of an individual's full potential and the complete development of their ability to enjoy and appreciate life. The highest level of psychological development, self-actualization, is only achievable once an individual have met their physiological, safety, belongingness, love and esteem needs. However, life tends to throw plenty of trials and tribulations that act as barriers to self-actualization, with Maslow estimating that just 1% of adults have self-actualized. Recent research into a federally controlled class of drugs has revealed an interesting fact: psychedelics have the ability to help people self-actualize. Individuals who…

ThursdayJul 28, 2022 11:26 am

DEA Sued Again for Denying Terminally Ill Patients Access to Psilocybin Therapy

The United States Drug Enforcement Administration (DEA) has been sued again for refusing to permit a doctor to treat patients with terminal illnesses using psilocybin therapy in accordance with state and federal Right To Try laws. Numerous trials have found that psilocybin, as well as MDMA, possess the potential to treat a range of mental health conditions, with the United States Food and Drug Administration (FDA) designating them as breakthrough therapies. Right To Try laws are aimed at increasing access to Schedule I investigational therapies that haven’t received approval for general use. The DEA is also facing political pressure from…

WednesdayJul 27, 2022 1:02 pm

Measure to Legalize Psychedelics Qualifies for November Ballot in Colorado

Voters in the state of Colorado now have the chance to vote for the legalization of psychedelics after a measure advocated for by the Natural Medicine Colorado campaign was approved for the November ballot. This approval comes less than a month after activists in the state submitted an estimated 100,000 more signatures for the legalization initiative than was required for it to qualify for the ballot. In a press release, Kevin Matthews, one of the initiative’s designated representatives, stated that the group of activists were proud of the work done and argued that psychedelic medicines held great promise for individuals…

TuesdayJul 26, 2022 2:36 pm

Compass Pathways Appoints New CEO

Compass Pathways has announced that it will be replacing its chief executive officer by the end of the month. The company’s founder, CEO and chair, George Goldsmith, will be replaced as CEO by Kabir Nath, effective Aug. 1, 2022. The mental health company announced on its website that George Goldsmith will continue serving as executive chair from Aug. 1 to Dec. 31, 2022, to assist in the transition. Goldsmith will retain his position as the executive chair once the handover is complete. He cofounded Compass Pathways PLC (NASDAQ: CMPS) in 2016 and led the firm from a startup to a…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks